...
首页> 外文期刊>Endocrine journal >Effects of Gonadotropin and Testosterone Treatments on Prostate Volume and Serum Prostate Specific Antigen Levels in Male Hypogonadism
【24h】

Effects of Gonadotropin and Testosterone Treatments on Prostate Volume and Serum Prostate Specific Antigen Levels in Male Hypogonadism

机译:促性腺激素和睾丸激素治疗对男性性腺功能减退症前列腺体积和血清前列腺特异性抗原水平的影响

获取原文
           

摘要

References(20) Cited-By(11) It is known that prostate specific antigen (PSA) is strongly androgen dependent, but little is known about the effects of gonadotropin and testosterone treatments on the prostate and serum PSA levels in male hypogonadism. We have therefore determined serum PSA levels before and 3 months after treatment in 13 patients with idiopathic hypogonadotropic hypogonadism (IHH) and 14 patients with Klinefelter's syndrome. Plasma FSH, LH, testosterone, PRL, testis and prostate volumes were also determined before and 3 months after treatments. Patients with IHH were treated with hCG/hMG and patients with Klinefelter's syndrome received testosterone treatment. PSA levels were determined by a kinetic enzyme immunoassay method. In patients with Klinefelter's syndrome FSH and LH levels were significantly decreased but total and free testosterone and PSA levels were significantly increased after 3 months of treatment. Right and left testicular volumes were not significantly changed whereas prostate volumes were significantly increased after treatment. In this group PSA levels were significantly and positively correlated with the prostate volume both before (r=0.54, P=0.048) and after treatment (r=0.61, P=0.012). In the IHH group total and free testosterone and PSA levels were significantly increased after gonadotropin treatment but FSH and LH levels did not change significantly. Right and left testicular volumes and the prostate volumes were also significantly increased after 3 months of gonadotropin treatment. In this group PSA levels were correlated with prostate volume before (r=0.74, P=0.004) treatment but not after therapy (r=0.35, P=NS). Our results show that serum PSA levels increase after gonadotropin and testosterone treatment in male hypogonadism, but this could not be used as an index for the evaluation of the androgen action in the treatment of male hypogonadism, since PSA levels following treatments were correlated with the prostate volume or T levels only in patients with Klinefelter's syndrome but not in the IHH group.
机译:参考文献(20)By-By(11)已知前列腺特异性抗原(PSA)强烈依赖雄激素,但对于促性腺激素和睾丸激素治疗对男性性腺功能减退症中前列腺和血清PSA水平的影响知之甚少。因此,我们确定了13例特发性性腺功能减退性腺功能减退症(IHH)和14例Klinefelter综合征患者在治疗前和治疗后3个月的血清PSA水平。在治疗前和治疗后3个月也测定血浆FSH,LH,睾丸激素,PRL,睾丸和前列腺体积。 IHH患者接受hCG / hMG治疗,Klinefelter综合征患者接受睾丸激素治疗。通过动力学酶免疫测定法确定PSA水平。治疗3个月后,克氏综合征患者的FSH和LH水平显着降低,但总睾丸激素水平和游离睾丸激素和PSA水平显着升高。治疗后左右睾丸体积没有明显变化,而前列腺体积明显增加。在该组中,治疗前(r = 0.54,P = 0.048)和治疗后(r = 0.61,P = 0.012),PSA水平均与前列腺体积显着正相关。在IHH组中,促性腺激素治疗后,总睾丸激素和游离睾丸激素及PSA的水平显着增加,但FSH和LH的水平没有明显改变。促性腺激素治疗3个月后,左右睾丸体积和前列腺体积也显着增加。在该组中,PSA水平与治疗前(r = 0.74,P = 0.004)的前列腺体积相关,而与治疗后无关(r = 0.35,P = NS)。我们的结果表明,在男性性腺功能减退症中,促性腺激素和睾丸激素治疗后血清PSA水平升高,但这不能作为评估男性性腺功能减退症中雄激素作用的指标,因为治疗后的PSA水平与前列腺相关。血脂或T水平仅在克氏综合征患者中有效,而在IHH组则没有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号